A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B
- Man Fung Yuen*
- , Chi Yi Chen
- , Chun Jen Liu
- , Wen Juei Jeng
- , Magdy Elkhashab
- , Carla S. Coffin
- , Won Kim
- , Susan Greenbloom
- , Alnoor Ramji
- , Young S. Lim
- , Yoon J. Kim
- , Scott K. Fung
- , Dong J. Kim
- , Jeong Won Jang
- , Kwan Sik Lee
- , Radhakrishnan P. Iyer
- , Chelsea Macfarlane
- , Kathy Jackson
- , Stephen A. Locarnini
- , Henry L.Y. Chan
*Corresponding author for this work
- The University of Hong Kong
- Chia-Yi Christian Hospital
- National Taiwan University
- University of Toronto
- University of Calgary
- Seoul National University
- Toronto Digestive Disease Associates
- Gastrointestinal Research Institute
- University of Ulsan
- Toronto General Hospital
- Hallym University
- The Catholic University of Korea
- Yonsei University
- Inc.
- Spring Bank Pharmaceuticals
- Royal Melbourne Hospital
- The Chinese University of Hong Kong
- Beth Israel Deaconess Medical Center
Research output: Contribution to journal › Journal Article › peer-review
28
Scopus
citations